{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:51:11Z","timestamp":1785401471275,"version":"3.56.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008021","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alopecia areata (AA) is a common, immune-mediated inflammatory disease characterized by nonscarring hair loss. Tyrosine kinase (TYK)2 mediates signalling of select proinflammatory cytokines [e.g. interleukin (IL)-12, IL-23 and type I interferons], which may play a role in the pathogenesis of AA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with\u00a0AA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were randomized 1 : 1 : 1 to oral placebo, deucravacitinib 6\u2005mg once daily, or deucravacitinib 6\u2005mg twice daily. At week 24, patients randomized to placebo were rerandomized 1 : 1 to deucravacitinib 6\u2005mg once daily or deucravacitinib 6\u2005mg twice daily until week 52. The primary efficacy endpoint was change from baseline in Severity of Alopecia Tool (SALT) score at week 24. Secondary endpoints were proportions of patients achieving \u2265 50% reduction from baseline in SALT score (SALT 50), SALT score \u2264 20, and Alopecia Areata Investigator Global Assessment score of 0 (clear) or 1 (almost clear) with \u2265 2-point improvement from baseline at week 24. This trial was terminated following database lock at week 24, but before primary data readout, owing to a strategic decision by the sponsor and not as a result of any observed, expected or perceived efficacy or safety findings with deucravacitinib treatment. Early termination did not affect study power.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 94 patients received placebo (n = 31), deucravacitinib 6\u2005mg once daily (n = 32), or deucravacitinib 6\u2005mg twice daily (n = 31). Baseline disease characteristics were balanced across treatment groups. No meaningful difference in change from baseline in SALT score at week 24 was observed between the deucravacitinib and placebo groups [6\u2005mg once daily: adjusted mean difference 1.5, 95% confidence interval (CI) \u22126.2 to 9.2, P = 0.701; 6\u2005mg twice daily: 8.2, 95% CI 0.2\u201316.2, P = 0.045]. Similarly, no differences were observed for any secondary endpoint. No new safety signals were identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This trial did not meet the efficacy endpoints and TYK2 inhibition by deucravacitinib may not play a major role in hair regrowth in patients with AA. The safety of deucravacitinib in patients with AA was consistent with the known safety profile of this TYK2 inhibitor.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljag109","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T12:37:09Z","timestamp":1774096629000},"page":"211-221","source":"Crossref","is-referenced-by-count":2,"title":["Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicentre, randomized, double-blinded, placebo-controlled trial"],"prefix":"10.1093","volume":"195","author":[{"given":"Brett","family":"King","sequence":"first","affiliation":[{"name":"Dermatology Physicians of Connecticut , Fairfield, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ehst","sequence":"additional","affiliation":[{"name":"Oregon Medical Research Center , Portland, OR ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Foley","sequence":"additional","affiliation":[{"name":"The University of Melbourne, St. Vincent\u2019s Hospital Melbourne, and Skin Health Institute , Melbourne, VIC ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Reygagne","sequence":"additional","affiliation":[{"name":"Centre de Sant\u00e9 Sabouraud, H\u00f4pital Saint Louis , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Ohyama","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Kyorin University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek C","family":"Szepietowski","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Venereology, and Clinical Immunology, Faculty of Medicine, Wroc\u0142aw University of Science and Technology , Wroc\u0142aw , ; , Wroc\u0142aw ,","place":["Poland Poland"]},{"name":"City\u00a0Clinic, Medical and Psychological Center , Wroc\u0142aw , ; , Wroc\u0142aw ,","place":["Poland Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoran","family":"Popmihajlov","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"De Leonardis","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Hippeli","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Treitel","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Johnson","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coryandar","family":"Gilvary","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vaile","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Daamen","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Passeron","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Nice, C\u00f4te d\u2019Azur University, Nice ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"2026071712540400900_ljag109-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2017.04.1141","article-title":"Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2026071712540400900_ljag109-B2","author":"U.S. Food and Drug Administration"},{"key":"2026071712540400900_ljag109-B3","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jaad.2016.04.035","article-title":"Health-related quality of life (HRQoL) among patients with alopecia areata (AA): a systematic review","volume":"75","author":"Liu","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2026071712540400900_ljag109-B4","volume-title":"Olumiant [package insert]","year":"2022"},{"key":"2026071712540400900_ljag109-B5","volume-title":"Litfulo [package insert]","year":"2023"},{"key":"2026071712540400900_ljag109-B6","volume-title":"Leqselvi [package insert]","year":"2024"},{"key":"2026071712540400900_ljag109-B7","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.3390\/cells10123397","article-title":"The role of serum Th1, Th2, and Th17 cytokines in patients with alopecia areata: clinical implications","volume":"10","author":"Wa\u015bkiel-Burnat","year":"2021","journal-title":"Cells"},{"key":"2026071712540400900_ljag109-B8","doi-asserted-by":"crossref","first-page":"1243556","DOI":"10.3389\/fimmu.2023.1243556","article-title":"Inhibition of T-cell activity in alopecia areata: recent developments and new directions","volume":"14","author":"Passeron","year":"2023","journal-title":"Front Immunol"},{"key":"2026071712540400900_ljag109-B9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nri1001","article-title":"Interleukin-12 and the regulation of innate resistance and adaptive immunity","volume":"3","author":"Trinchieri","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"2026071712540400900_ljag109-B10","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jaci.2015.06.032","article-title":"Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17\/TH22 skewing","volume":"136","author":"Su\u00e1rez-Fari\u00f1as","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"2026071712540400900_ljag109-B11","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.jaci.2018.06.029","article-title":"An integrated model of alopecia areata biomarkers highlights both T(H)1 and T(H)2 upregulation","volume":"142","author":"Song","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2026071712540400900_ljag109-B12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jaci.2015.11.001","article-title":"Extensive alopecia areata is reversed by IL-12\/IL-23p40 cytokine antagonism","volume":"137","author":"Guttman-Yassky","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2026071712540400900_ljag109-B13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-2133.2010.09775.x","article-title":"Type 1 interferon signature in the scalp lesions of alopecia areata","volume":"163","author":"Ghoreishi","year":"2010","journal-title":"Br J Dermatol"},{"key":"2026071712540400900_ljag109-B14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/jdv.12932","article-title":"Plasmacytoid dendritic cells in alopecia areata: missing link?","volume":"30","author":"Abou Rahal","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026071712540400900_ljag109-B15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci Transl Med"},{"key":"2026071712540400900_ljag109-B16","volume-title":"Sotyktu [package insert]","year":"2022"},{"key":"2026071712540400900_ljag109-B17","volume-title":"Sotyktu [package insert]","year":"2022"},{"key":"2026071712540400900_ljag109-B18","volume-title":"Sotyktu [product monograph]","year":"2022"},{"key":"2026071712540400900_ljag109-B19","volume-title":"Sotyktu [product information]","year":"2022"},{"key":"2026071712540400900_ljag109-B20","volume-title":"Sotyktu [European summary of product characteristics]","year":"2023"},{"key":"2026071712540400900_ljag109-B21","volume-title":"Sotyktu [package insert]","year":"2023"},{"key":"2026071712540400900_ljag109-B22","volume-title":"Sotyktu [package insert]","year":"2023"},{"key":"2026071712540400900_ljag109-B23","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J Med Chem"},{"issue":"11 Suppl.","key":"2026071712540400900_ljag109-B24","doi-asserted-by":"crossref","first-page":"S337","DOI":"10.1016\/j.jid.2023.09.035","article-title":"Preclinical ex vivo and in vivo evidence supporting selective inhibition of tyrosine kinase 2-dependent, IL-12-mediated signaling as a novel pharmacological strategy for alopecia areata management [abstract 27]","volume":"143","author":"Edelkamp","year":"2023","journal-title":"J Invest Dermatol"},{"key":"2026071712540400900_ljag109-B25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/cts.13435","article-title":"First-in-human study of deucravacitinib: a selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2","volume":"16","author":"Catlett","year":"2023","journal-title":"Clin Transl Sci"},{"key":"2026071712540400900_ljag109-B26","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","article-title":"Alopecia areata investigational assessment guidelines\u2014part II. National Alopecia Areata Foundation","volume":"51","author":"Olsen","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"2026071712540400900_ljag109-B27","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bjd.18883","article-title":"The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials","volume":"183","author":"Wyrwich","year":"2020","journal-title":"Br J Dermatol"},{"key":"2026071712540400900_ljag109-B28","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/bjd\/ljad253","article-title":"When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials","volume":"189","author":"King","year":"2023","journal-title":"Br J Dermatol"},{"key":"2026071712540400900_ljag109-B29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2026071712540400900_ljag109-B30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, Program fOr Evaluation of TYK2 inhibitor psoriasis second phase 3 trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2026071712540400900_ljag109-B31","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/jdv.19925","article-title":"Deucravacitinib in moderate to severe plaque psoriasis: pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)","volume":"38","author":"Strober","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026071712540400900_ljag109-B32","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"2026071712540400900_ljag109-B33","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jaci.2021.10.036","article-title":"Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers","volume":"149","author":"Guttman-Yassky","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2026071712540400900_ljag109-B34","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40257-023-00764-w","article-title":"Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2)","volume":"24","author":"Kwon","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"2026071712540400900_ljag109-B35","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/jdv.19665","article-title":"Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2","volume":"38","author":"Senna","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026071712540400900_ljag109-B36","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial","volume":"401","author":"King","year":"2023","journal-title":"Lancet"},{"key":"2026071712540400900_ljag109-B37","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jaad.2024.06.097","article-title":"Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the Phase 3 randomized, controlled trial (THRIVE-AA1)","volume":"91","author":"King","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2026071712540400900_ljag109-B38","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljag109\/67637955\/ljag109.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/195\/2\/211\/67637955\/ljag109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/195\/2\/211\/67637955\/ljag109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:54:11Z","timestamp":1784307251000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/195\/2\/211\/8555659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,3,30]]},"published-print":{"date-parts":[[2026,7,17]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljag109","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,3,30]]}}}